Kartik Chandran

This study identifies phosphatidylserine receptors as critical for CCHFV infection and shows that targeting these receptors can protect against viral disease.

This study identifies key glycoprotein residues that enhance the efficacy of a CCHFV vaccine by modulating cleavage and fusogenicity in animal models.

This study identifies expanded protocadherin-1 usage by hantaviruses and shows differential neutralization by antibodies.

The paper identifies female-specific m6A RNA methylation changes in mouse livers under high-fat diet that correlate with post-transcriptional metabolic adaptations and protein remodeling.

This paper predicts filovirus host susceptibility in bats by integrating molecular binding data with ecological and phylogenetic information across 1,300 species.

This study uses molecular dynamics simulations to analyze how mutations in the SHC014-CoV spike protein affect its structural dynamics and allosteric communication, revealing mechanisms that enhance viral entry.

The paper determines high-resolution structures of hantavirus glycoprotein tetramers and related complexes, revealing new insights into their organization and function, and evaluates their potential for vaccine design.

This paper identifies an adaptive mutation in the WIV1-CoV spike protein that enhances ACE2 binding and cell entry by altering spike dynamics, suggesting alternative spillover mechanisms for bat sarbecoviruses.

This study identifies GP38 as a viral toxin causing vascular leak and shows that specific GP38-targeting antibodies block this effect in vitro and in vivo.

The paper describes the structure and immunogenicity of a stabilized CCHFV heterotrimeric glycoprotein complex and shows it provides 40% protection against viral challenge in mice.

The paper investigates how SARS-like bat coronaviruses evolve enhanced receptor binding and cell entry through specific genetic substitutions.

This study designs stabilized SARS-CoV-2 S2 immunogens using simulation-driven approaches, showing improved stability and immunogenicity.

This paper demonstrates a viral vaccine strategy using BCG-induced Th cells to enhance antibody responses against Ebola virus, providing protection in a mouse model.

The paper identifies non-neutralizing antibodies from CCHFV survivors that target multiple regions on GP38, showing protective efficacy in rodent models.

This study shows Ebola virus can infect boa constrictor cells without causing cytopathic effect or requiring genomic adaptation, while Marburg virus cannot.